The Online Investor
Questcor Pharmaceuticals Inc (QCOR)

Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with autoimmune and inflammatory disorders. Co. also supplies contract manufacturing services to the global pharmaceutical and biotechnology industry through its wholly-owned subsidiary, BioVectra Inc. Co. manages its operations through two operating segments: Questcor Pharmaceuticals, Inc., whose primary product is H.P. Acthar® Gel (repository corticotropin injection), or Acthar, an injectable drug for the treatment of 19 indications; and BioVectra, Inc.; which is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry.
Company Name: 
Questcor Pharmaceuticals Inc
Stock buyback: 
QCOR buyback
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree QCOR Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Questcor Pharmaceuticals Inc (QCOR) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.